Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 45, 2011, Pages

  Goto, June ^a   Talos, Delia M ^b,c   Klein, Peter ^b,c   Qin, Wei ^a,g   Chekaluk, Yvonne I ^a   Anderl, Stefanie ^a   Malinowska, Izabela A ^a   Di Nardo, Alessia ^b,c   Bronson, Roderick T ^c   Chan, Jennifer A ^d   Vinters, Harry V ^e   Kernie, Steven G ^f,h   Jensen, Frances E ^b,c   Sahin, Mustafa ^b,c   Kwiatkowski, David J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e UCLA MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g SHANGHAI JIAO TONG UNIVERSITY   (China)

^h Morgan Stanley Children's Hospital ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CRE RECOMBINASE; DOXYCYCLINE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; NESTIN; RAPAMYCIN; TSC1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEVELOPMENT; CELL ORGANELLE; CELL VACUOLE; CONTROLLED STUDY; DISEASE SEVERITY; EMBRYO; ENDOPLASMIC RETICULUM STRESS; EPILEPSY; FEMALE; GENE MUTATION; GIANT CELL; HUMAN; HUMAN TISSUE; LYSOSOME; MALE; MITOCHONDRION; MOUSE; NEURAL STEM CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; SUDDEN DEATH; TUBEROUS SCLEROSIS;

ANIMALS; BLOTTING, WESTERN; CELL SURVIVAL; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICROSCOPY, ELECTRON; MICROSCOPY, FLUORESCENCE; NEURONS; POLYMERASE CHAIN REACTION; SIROLIMUS; STEM CELLS; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA;

EID: 81055126193     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1106454108     Document Type: Article

References (58)

1. Jozwiak J, Jozwiak S, Wlodarski P (2008) Possible mechanisms of disease development in tuberous sclerosis. Lancet Oncol 9(1):73-79.
2. Kwiatkowski DJ, Thiele EA, Whittemore VH, eds (2010) Tuberous Sclerosis Complex: Genes, Clinical Features, and Therapeutics (Wiley-VCH, Weinheim, Germany), p 432.
3. Thiele EA (2004) Managing epilepsy in tuberous sclerosis complex. J Child Neurol 19:680-686.
4. Holmes GL, Stafstrom CE; Tuberous Sclerosis Study Group (2007) Tuberous sclerosis complex and epilepsy: Recent developments and future challenges. Epilepsia 48:617-630. (Pubitemid 46587608)
5. Doherty C, Goh S, Young Poussaint T, Erdag N, Thiele EA (2005) Prognostic significance of tuber count and location in tuberous sclerosis complex. J Child Neurol 20:837-841. (Pubitemid 43124477)
6. Winterkorn EB, Pulsifer MB, Thiele EA (2007) Cognitive prognosis of patients with tuberous sclerosis complex. Neurology 68:62-64. (Pubitemid 46058555)
7. Yamanouchi H, Jay V, Rutka JT, Takashima S, Becker LE (1997) Evidence of abnormal differentiation in giant cells of tuberous sclerosis. Pediatr Neurol 17(1):49-53. (Pubitemid 27387919)
8. Crino PB, Trojanowski JQ, Dichter MA, Eberwine J (1996) Embryonic neuronal markers in tuberous sclerosis: Single-cell molecular pathology. Proc Natl Acad Sci USA 93:14152-14157. (Pubitemid 26424261)
9. Talos DM, Kwiatkowski DJ, Cordero K, Black PM, Jensen FE (2008) Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers. Ann Neurol 63:454-465. (Pubitemid 351614711)
10. Jozwiak J, Jozwiak S (2007) Giant cells: Contradiction to two-hit model of tuber formation? Cell Mol Neurobiol 27:251-261.
11. Huttenlocher PR, Wollmann RL (1991) Cellular neuropathology of tuberous sclerosis. Ann N Y Acad Sci 615(1):140-148.
12. Bordarier C, Lellouch-Tubiana A, Robain O (1994) Cardiac rhabdomyoma and tuberous sclerosis in three fetuses: A neuropathological study. Brain Dev 16:467-471.
13. Park SH, et al. (1997) Tuberous sclerosis in a 20-week gestation fetus: Immunohistochemical study. Acta Neuropathol 94(2):180-186.
14. Wei JJ, et al. (2002) Tuberous sclerosis in a 19-week fetus: Immunohistochemical and molecular study of hamartin and tuberin. Pediatr Dev Pathol 5:448-464.
15. van Slegtenhorst M, et al. (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277:805-808.
16. Nellist M, et al.; European Chromosome 16 Tuberous Sclerosis Consortium (1993) Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75:1305-1315. (Pubitemid 24021906)
17. Sabatini DM (2006) mTOR and cancer: Insights into a complex relationship. Nat Rev Cancer 6:729-734.
18. Fingar DC, Blenis J (2004) Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23:3151-3171. (Pubitemid 38638827)
19. Laplante M, Sabatini DM (2009) An emerging role of mTOR in lipid biosynthesis. Curr Biol 19:R1046-R1052.
20. Porstmann T, et al. (2008) SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 8:224-236.
21. Ma XM, Blenis J (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10:307-318.
22. Cunningham JT, et al. (2007) mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 450:736-740. (Pubitemid 350207689)
23. Jung CH, Ro SH, Cao J, Otto NM, Kim DH (2010) mTOR regulation of autophagy. FEBS Lett 584:1287-1295.
24. Ozcan U, et al. (2008) Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell 29:541-551. (Pubitemid 351384644)
25. Di Nardo A, et al. (2009) Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner. J Neurosci 29:5926-5937.
26. Finlay GA, Thannickal VJ, Fanburg BL, Kwiatkowski DJ (2005) Platelet-derived growth factor-induced p42/44 mitogen-activated protein kinase activation and cellular growth is mediated by reactive oxygen species in the absence of TSC2/tuberin. Cancer Res 65:10881-10890. (Pubitemid 41713356)
27. Uhlmann EJ, et al. (2002) Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol 52:285-296. (Pubitemid 35001494)
28. Meikle L, et al. (2007) A mouse model of tuberous sclerosis:Neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci 27:5546-5558. (Pubitemid 350021088)
29. Way SW, et al. (2009) Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse. Hum Mol Genet 18:1252-1265.
30. Yu TS, Dandekar M, Monteggia LM, Parada LF, Kernie SG (2005) Temporally regulated expression of Cre recombinase in neural stem cells. Genesis 41(4):147-153. (Pubitemid 40656684)
31. Anderl S, Freeland M, Kwiatkowski DJ, Goto J (2011) Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex. Hum Mol Genet, 10.1093/hmg/ddr393.
32. Ikenoue T, Inoki K, Yang Q, Zhou X, Guan KL (2008) Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J 27:1919-1931.
33. Facchinetti V, et al. (2008) The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 27:1932-1943.
34. Blümcke I, et al. (2011) The clinicopathologic spectrum of focal cortical dysplasias: A consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia 52:158-174.
35. Choi YJ, et al. (2008) Tuberous sclerosis complex proteins control axon formation. Genes Dev 22:2485-2495.
36. Chow DK, et al. (2009) Laminar and compartmental regulation of dendritic growth in mature cortex. Nat Neurosci 12(2):116-118.
37. Kwon CH, et al. (2006) Pten regulates neuronal arborization and social interaction in mice. Neuron 50:377-388.
38. Kimball SR, Fabian JR, Pavitt GD, Hinnebusch AG, Jefferson LS (1998) Regulation of guanine nucleotide exchange through phosphorylation of eukaryotic initiation factor eIF2alpha. Role of the alpha- and delta-subunits of eiF2b. J Biol Chem 273:12841-12845. (Pubitemid 28246840)
39. Harding HP, Zhang YH, Ron D (1999) Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 397:271-274. (Pubitemid 29051178)
40. Kaufman RJ (1999) Stress signaling from the lumen of the endoplasmic reticulum: Coordination of gene transcriptional and translational controls. Genes Dev 13:1211-1233.
41. Boer K, et al. (2010) Gene expression analysis of tuberous sclerosis complex cortical tubers reveals increased expression of adhesion and inflammatory factors. Brain Pathol 20:704-719.
42. Sancak Y, et al. (2008) The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320:1496-1501. (Pubitemid 351929429)
43. Sancak Y, et al. (2010) Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141:290-303.
44. Yu L, et al. (2010) Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature 465:942-946.
45. Wong M, et al. (2003) Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model. Ann Neurol 54:251-256. (Pubitemid 36909626)
46. Zeng LH, Bero AW, Zhang B, Holtzman DM, Wong M (2010) Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of Tuberous Sclerosis Complex. Neurobiol Dis 37:764-771.
47. Crino PB, Aronica E, Baltuch G, Nathanson KL (2010) Biallelic TSC gene inactivation in tuberous sclerosis complex. Neurology 74:1716-1723.
48. Mizuguchi M, Kato M, Yamanouchi H, Ikeda K, Takashima S (1996) Loss of tuberin from cerebral tissues with tuberous sclerosis and astrocytoma. Ann Neurol 40:941-944. (Pubitemid 27044617)
49. Feliciano DM, Su T, Lopez J, Platel JC, Bordey A (2011) Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice. J Clin Invest 121:1596-1607.
50. Meikle L, et al. (2008) Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: Effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 28:5422-5432.
51. Zeng LH, Xu L, Gutmann DH, Wong M (2008) Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 63:444-453. (Pubitemid 351614710)
52. Lam C, et al. (2010) Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors. Pediatr Blood Cancer 54:476-479.
53. Krueger DA, et al. (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363:1801-1811.
54. Tyler WA, et al. (2009) Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation. J Neurosci 29:6367-6378.
55. Narayanan SP, Flores AI, Wang F, Macklin WB (2009) Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J Neurosci 29:6860-6870.
56. Mao XH, Fujiwara Y, Orkin SH (1999) Improved reporter strain for monitoring Cre recombinase-mediated DNA excisions in mice. Proc Natl Acad Sci USA 96:5037-5042. (Pubitemid 29214531)
57. Kozlowski P, Lin M, Meikle L, Kwiatkowski DJ (2007) Robust method for distinguishing heterozygous from homozygous transgenic alleles by multiplex ligation-dependent probe assay. Biotechniques, 42:584, 586, 588.
58. Liang MC, et al. (2010) TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene 29:1588-1597.